Acrivon Therapeutics, Inc. (ACRV) vs Rani Therapeutics Holdings, Inc. (RANI)

Acrivon Therapeutics, Inc. and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Acrivon Therapeutics, Inc. and Rani Therapeutics Holdings, Inc. are of similar size ($79.9M and $74.6M). Acrivon Therapeutics, Inc. has the higher net margin (0.00% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Acrivon Therapeutics, Inc. leads on 7 and Rani Therapeutics Holdings, Inc. on 5.

Valuation

Metric ACRV RANI Biotechnology median
P/E n/m n/m 10.26
P/S n/m 19.28 9.18
P/B 0.76 2.03 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.31 n/m 0.65
EV/Sales n/m 11.82 8.98
Earnings yield (118.99%) (51.92%) (34.89%)
Free cash flow yield (97.02%) (20.90%) (24.52%)

Profitability

Metric ACRV RANI Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (652.78%) 0.00%
Net margin 0.00% (596.97%) 0.00%
Free cash flow margin 0.00% (402.83%) 0.00%
Return on equity (64.63%) (155.24%) (50.12%)
Return on assets (57.61%) (77.54%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACRV RANI Biotechnology median
Revenue growth (TTM) — 78.73% 6.26%
EPS growth (last fiscal year) 15.13% 57.14% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRV RANI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.99 5.31 4.89
Net debt to EBITDA 1.43 1.33 1.01

Dividend

Metric ACRV RANI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACRV RANI Biotechnology median
Market cap 74.57m 79.85m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack